ORLENI, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 486
AS - Asia 388
EU - Europa 298
SA - Sud America 133
AF - Africa 90
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 8
Totale 1.412
Nazione #
US - Stati Uniti d'America 437
SG - Singapore 139
BR - Brasile 100
CN - Cina 76
DE - Germania 61
HK - Hong Kong 57
FI - Finlandia 37
IT - Italia 36
PL - Polonia 28
RU - Federazione Russa 21
GB - Regno Unito 15
VN - Vietnam 14
IN - India 11
FR - Francia 10
JP - Giappone 10
NL - Olanda 9
TR - Turchia 9
CA - Canada 8
AR - Argentina 7
AT - Austria 7
BA - Bosnia-Erzegovina 7
CO - Colombia 7
AO - Angola 6
ID - Indonesia 6
IE - Irlanda 6
MA - Marocco 6
MX - Messico 6
CW - ???statistics.table.value.countryCode.CW??? 5
GT - Guatemala 5
SA - Arabia Saudita 5
AD - Andorra 4
AZ - Azerbaigian 4
BD - Bangladesh 4
BE - Belgio 4
CG - Congo 4
CL - Cile 4
DZ - Algeria 4
HU - Ungheria 4
KG - Kirghizistan 4
KR - Corea 4
LT - Lituania 4
MK - Macedonia 4
NC - Nuova Caledonia 4
RS - Serbia 4
UA - Ucraina 4
VC - Saint Vincent e Grenadine 4
YT - Mayotte 4
AE - Emirati Arabi Uniti 3
BB - Barbados 3
BO - Bolivia 3
CV - Capo Verde 3
DJ - Gibuti 3
DK - Danimarca 3
GE - Georgia 3
HR - Croazia 3
KE - Kenya 3
KY - Cayman, isole 3
MG - Madagascar 3
MR - Mauritania 3
NP - Nepal 3
PH - Filippine 3
PK - Pakistan 3
PS - Palestinian Territory 3
PT - Portogallo 3
PY - Paraguay 3
RE - Reunion 3
RO - Romania 3
RW - Ruanda 3
TH - Thailandia 3
TZ - Tanzania 3
UG - Uganda 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
BF - Burkina Faso 2
BG - Bulgaria 2
BJ - Benin 2
BS - Bahamas 2
BW - Botswana 2
BY - Bielorussia 2
CH - Svizzera 2
CM - Camerun 2
CR - Costa Rica 2
CU - Cuba 2
DM - Dominica 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
EG - Egitto 2
GM - Gambi 2
GN - Guinea 2
GP - Guadalupe 2
HN - Honduras 2
JO - Giordania 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
ML - Mali 2
MY - Malesia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PE - Perù 2
Totale 1.350
Città #
Singapore 105
Ashburn 88
Hong Kong 57
Munich 37
Santa Clara 26
Chandler 23
Beijing 22
Bytom 21
Boardman 19
Fairfield 16
Chicago 15
Turku 15
Cambridge 14
Los Angeles 14
Helsinki 13
Dallas 11
Buffalo 9
San Diego 9
São Paulo 9
Seattle 8
Hefei 7
Houston 7
New York 7
Tokyo 7
Trieste 7
Falkenstein 6
Frankfurt am Main 6
London 6
Luanda 6
Ann Arbor 5
Ho Chi Minh City 5
Lappeenranta 5
Redondo Beach 5
Andorra la Vella 4
Baku 4
Bishkek 4
Charlotte 4
Kingstown 4
Medford 4
Noumea 4
Princeton 4
Rio de Janeiro 4
San Francisco 4
Wilmington 4
Woodbridge 4
Brazzaville 3
Bridgetown 3
Chennai 3
Cochabamba 3
Des Moines 3
Djibouti 3
George Town 3
Guatemala City 3
Jakarta 3
Jeddah 3
Kampala 3
Kigali 3
Mamoudzou 3
Nairobi 3
Nouakchott 3
Praia 3
Pristina 3
Salt Lake City 3
Toronto 3
Warsaw 3
Willemstad 3
Üsküdar 3
Amman 2
Apia 2
Arusha 2
Auckland 2
Bamako 2
Bangkok 2
Banja Luka 2
Banjul 2
Belluno 2
Belo Horizonte 2
Boston 2
Brasília 2
Brooklyn 2
Conakry 2
Cotonou 2
Council Bluffs 2
Curitiba 2
Dakar 2
Dubai 2
Elk Grove Village 2
Fort Worth 2
Fortaleza 2
Fossò 2
Goiânia 2
Guarulhos 2
Hanoi 2
Harare 2
Havana 2
Khartoum 2
Lucca 2
Lusaka 2
Maipú 2
Managua 2
Totale 790
Nome #
Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application 110
A LC–MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma 101
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 95
A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring 92
Oral targeted therapies in oncology: bioanalytical methods for therapeutic drug monitoring and pharmacokinetic investigations 84
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 75
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactions 75
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring 71
A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring 69
The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure 68
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring 68
Pharmacology and pharmacokinetics of tazemetostat 67
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 64
Bioanalytical Methods for Poly(ADP-Ribose) Polymerase Inhibitor Quantification: A Review for Therapeutic Drug Monitoring 62
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 60
A fast and validated LC-MS/MS method to quantify lenvatinib in dried blood spot 60
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 57
Increased plasma imatinib exposure and toxicity in chronically treated GIST patients with SARS-CoV-2 infection: a case series 53
Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis 53
Quantitation of tazemetostat in human plasma using liquid chromatography–tandem mass spectrometry 50
Totale 1.434
Categoria #
all - tutte 5.221
article - articoli 5.050
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.271


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202126 0 0 0 5 0 0 0 8 4 9 0 0
2021/202244 0 0 2 0 2 16 0 3 3 6 2 10
2022/202354 7 5 3 4 10 5 0 2 11 2 3 2
2023/202436 0 5 0 1 4 10 4 4 3 0 5 0
2024/2025642 1 66 26 23 47 36 26 52 39 51 96 179
2025/2026605 169 140 290 6 0 0 0 0 0 0 0 0
Totale 1.434